# Fourth Swedish National Pension Fund

> Fourth Swedish National Pension Fund is a VC fund backing Biotechnology. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Stockholm, Sweden
- Total investments: 13
- Last investment: Apr 2026
- Lead investor: 31%
- Last updated: Aug 2026
- Website: http://www.ap4.se/en

Fourth Swedish National Pension Fund is a VC fund in Stockholm focused on Biotechnology and Manufacturing. One of five buffer funds in the Swedish pension system.

## Contacts

5 contacts available for Fourth Swedish National Pension Fund. Shizune tracks 1 team members at Fourth Swedish National Pension Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/fourth-swedish-national-pension-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 31% |
| Manufacturing | 3 | 23% |
| Pharmaceutical | 3 | 23% |
| Software | 2 | 15% |
| Electronics | 2 | 15% |

29 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 7 | 54% |
| Venture - Series Unknown | 2 | 15% |
| Series C | 1 | 8% |
| Series E | 1 | 8% |
| Private Equity | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 11 | 85% |
| Denmark | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Per Colleen | Head of Fundamental Equities | 1 | https://shizune.co/investors/profile/per-colleen |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Egetis Therapeutics | Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development. | $38.3M | Post-IPO Equity | Apr 21, 2026 |  |
| Intea Fastigheter | Intea Fastigheter is a real estate company that develops social infrastructure, commercial, and industrial properties. | $52.7M | Post-IPO Equity | Nov 26, 2025 |  |
| Egetis Therapeutics | Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development. | $29.5M | Post-IPO Equity | Sep 30, 2024 |  |
| Hansa Biopharma | Hansa Biopharma is a biopharmaceutical company that develops immunomodulatory treatments for people living with rare immunological diseases. They concentrate on creating novel, life-saving and life-changing treatments that can meet the critical, unmet medical needs of individuals with uncommon immunological disorders. To target pathogenic ordisease-causing antibodies, they developed its proprietary antibody-cleaving enzyme technology platform. The company's diverse therapeutic pipeline has the potential to address significant unmet medical needs in transplantation, autoimmune diseases, gene therapy, and oncology indications. | $34.2M | Post-IPO Equity | Apr 12, 2024 |  |
| Sivers Semiconductors | Sivers Semiconductors is a renowned supplier, publicly traded under SIVE. The wholly owned subsidiaries Sivers IMA and CST Global develop, manufacture and sell cutting-edge chips, components, modules, and subsystems based on proprietary advanced semiconductor technology in microwave, millimeter wave and optical semiconductors. Headquarters inStockholm, Sweden. | $150M | Post-IPO Equity | Apr 04, 2023 |  |
| Ovzon | Ovzon provides mobile satellite service that combines the mobility of mobile satellite telephony and broadband capacity from fixed satellite systems, using patented technology. | $19M | Post-IPO Equity | Feb 03, 2023 |  |
| Occlutech | Occlutech, founded in 2003, is a rapidly expanding European hi-tech company specializing in developing and manufacturing cardiac occlusion devices and other vascular implants. The company has developed several new, unique products using a wide range of state of the art technological capabilities and proprietary know-how. | $49.3M | Private Equity | Dec 21, 2021 |  |
| Funnel | Funnel is here to put an end to manual data collection. Funnel integrates with all marketing and advertising platforms and allows you to feed your data anywhere you want it. Out-of-the-box integrations with 400+ data sources.With Funnel, you will have the freedom to feed your data into any tool you like. Automatically feed data into your BusinessIntelligence tool, your Data Warehouse, Google Sheets, Google Data Studio, Google Analytics or any other visualization tool. Funnel caters to e-commerce companies, media agencies, brands, b2b businesses, mobile apps, and gaming companies. Fredrik Skantze and Per Made founded it in 2014. Offices in Stockholm (HQ) and Boston. | $65.8M | Series C | Oct 12, 2021 |  |
| Northvolt | Northvolt develops sustainable lithium-ion batteries in conjunction with R&D, industrialization, and recycling to support clean energy. It provides electrification and renewable energy storage designed for lithium-ion battery plant to produce batteries for electric vehicles. Northvolt's product is an environment-friendly batterymanufactured with minimal carbon footprint and with recycling technology without compromising with important eco-systems, enabling the auto industry to replace fossil fuels with electricity in an efficient manner. The company aims to establish a supply of sustainable battery cells and systems.In 2016, Paolo Cerruti and Peter Carlsson headquartered the company in Stockholm, Stockholms Lan. | $2.8B | Venture - Series Unknown | Jun 09, 2021 |  |
| Ascelia Pharma | Ascelia Pharma is a drug development company dedicated to oncology, focusing on the production of new medicines to enhance life expectancy. | $23.7M | Post-IPO Equity | Mar 17, 2021 |  |

10 of 13 investments shown.

## Co-investors
- [Andra AP-fonden](https://shizune.co/investors/profile/andra-ap-fonden) — VC Fund, 3 deals together
- [Frazier Life Sciences](https://shizune.co/investors/profile/frazier-life-sciences) — VC Fund, 2 deals together
- [Svenska Handelsbanken](https://shizune.co/investors/profile/handelsbanken) — VC Fund, 2 deals together
- [Healthinvest Partners](https://shizune.co/investors/profile/healthinvest-partners) — VC Fund, 2 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 2 deals together
- [Third Swedish National Pension Fund](https://shizune.co/investors/profile/third-swedish-national-pension-fund) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Fourth Swedish National Pension Fund invest in?

Fourth Swedish National Pension Fund invests primarily in Biotechnology, Manufacturing and Pharmaceutical startups, most often at Post-IPO Equity and Venture - Series Unknown stage. Most of the 13 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Fourth Swedish National Pension Fund?

Public channels for Fourth Swedish National Pension Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Fourth Swedish National Pension Fund?

The team at Fourth Swedish National Pension Fund includes Per Colleen (Head of Fundamental Equities). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co